BioCentury | Feb 26, 2021
Emerging Company Profile

Immune-Onc building broad pipeline of myeloid checkpoint inhibitors

...immune-suppressing into tumor-suppressing agents.The Palo Alto-based company was co-founded by serial entrepreneur Guo-Liang Yu, an OrbiMed...
BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

...Bioscience in 2016, has raised at least $239 million in venture money from investors including OrbiMed...
...Merchant Bank and Ping An Ventures. Co-founder and CEO Yu is a venture partner at OrbiMed...
BioCentury | Feb 25, 2021
Deals

Feb. 24 Quick Takes: ICON buying PRA in $12B CRO deal; plus venture rounds for Yisheng, Xilio, Truvian, Lyvgen, AmacaThera, and more

...developmentYisheng Biopharma Co. Ltd. raised $130 million in a series B round co-led by Oceanpine and OrbiMed...
BioCentury | Feb 24, 2021
Deals

Feb. 23 Quick Takes: BGI raises $300M, plus a $230M C round for Clover, Day One, Waksal’s Graviton, Asalyxa

...oversubscribed series C round co-led by GL Ventures and Temasek. New investors Oceanpine Capital and OrbiMed...
BioCentury | Feb 22, 2021
Management Tracks

Fresh from $21B Gilead deal, Immunomedics vet Malik to lead newly rebranded precision medicines company Fore

...September from an investor syndicate that included Pontifax, OrbiMed...
BioCentury | Feb 19, 2021
Finance

Evox eyes clinic for internal pipeline with £69.2M series C round

...sole investor in the company’s 2016 A round, also participated in the series C alongside OrbiMed...
BioCentury | Jan 23, 2021
Finance

2020’s most active biotech VCs: Data Byte

...By Gunjan ohri, data content analyst OrbiMed Advisors continued to lead the pack in terms of...
...VCs by number of biotech deals each participated in at least 30 rounds from 2015-20. OrbiMed...
...number of venture rounds of any series, and excludes venture debt.  Source: BioCentury’s BCIQ database Gunjan Ohri OrbiMed...
BioCentury | Jan 15, 2021
Product Development

Delfi and Earli series A rounds show there’s room for new entrants in early cancer detection

...as bigger players consolidate via M&A and prepare for commercial launch.Delfi Diagnostics Inc. raised an OrbiMed-led...
...studies to detect specific cancers like lung cancer in high-risk individuals. In addition to leader OrbiMed...
BioCentury | Jan 12, 2021
Finance

Jan. 11 Quick Takes: Megarounds for Valo, Visen; plus NuProbe, Sensei

...development of its endocrinology therapies in Greater China. Sequoia China led the round with participation from OrbiMed...
BioCentury | Jan 8, 2021
Deals

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

...Also participating in the series B were Surveyor Capital, Invus, Wellington Management Co., Nexttech Invest, OrbiMed...
...Epidermal growth factor receptor 2 BC Staff CVnCoV CT-0508 (CARMA-0508) ARGX-113 (efgartigimod) Bayer AG CureVac N.V. Boxer Capital EcoR1 Capital Omega Funds Vida Ventures Surveyor Capital Invus Wellington Management OrbiMed Casdin...
Items per page:
1 - 10 of 1180
BioCentury | Feb 26, 2021
Emerging Company Profile

Immune-Onc building broad pipeline of myeloid checkpoint inhibitors

...immune-suppressing into tumor-suppressing agents.The Palo Alto-based company was co-founded by serial entrepreneur Guo-Liang Yu, an OrbiMed...
BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

...Bioscience in 2016, has raised at least $239 million in venture money from investors including OrbiMed...
...Merchant Bank and Ping An Ventures. Co-founder and CEO Yu is a venture partner at OrbiMed...
BioCentury | Feb 25, 2021
Deals

Feb. 24 Quick Takes: ICON buying PRA in $12B CRO deal; plus venture rounds for Yisheng, Xilio, Truvian, Lyvgen, AmacaThera, and more

...developmentYisheng Biopharma Co. Ltd. raised $130 million in a series B round co-led by Oceanpine and OrbiMed...
BioCentury | Feb 24, 2021
Deals

Feb. 23 Quick Takes: BGI raises $300M, plus a $230M C round for Clover, Day One, Waksal’s Graviton, Asalyxa

...oversubscribed series C round co-led by GL Ventures and Temasek. New investors Oceanpine Capital and OrbiMed...
BioCentury | Feb 22, 2021
Management Tracks

Fresh from $21B Gilead deal, Immunomedics vet Malik to lead newly rebranded precision medicines company Fore

...September from an investor syndicate that included Pontifax, OrbiMed...
BioCentury | Feb 19, 2021
Finance

Evox eyes clinic for internal pipeline with £69.2M series C round

...sole investor in the company’s 2016 A round, also participated in the series C alongside OrbiMed...
BioCentury | Jan 23, 2021
Finance

2020’s most active biotech VCs: Data Byte

...By Gunjan ohri, data content analyst OrbiMed Advisors continued to lead the pack in terms of...
...VCs by number of biotech deals each participated in at least 30 rounds from 2015-20. OrbiMed...
...number of venture rounds of any series, and excludes venture debt.  Source: BioCentury’s BCIQ database Gunjan Ohri OrbiMed...
BioCentury | Jan 15, 2021
Product Development

Delfi and Earli series A rounds show there’s room for new entrants in early cancer detection

...as bigger players consolidate via M&A and prepare for commercial launch.Delfi Diagnostics Inc. raised an OrbiMed-led...
...studies to detect specific cancers like lung cancer in high-risk individuals. In addition to leader OrbiMed...
BioCentury | Jan 12, 2021
Finance

Jan. 11 Quick Takes: Megarounds for Valo, Visen; plus NuProbe, Sensei

...development of its endocrinology therapies in Greater China. Sequoia China led the round with participation from OrbiMed...
BioCentury | Jan 8, 2021
Deals

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

...Also participating in the series B were Surveyor Capital, Invus, Wellington Management Co., Nexttech Invest, OrbiMed...
...Epidermal growth factor receptor 2 BC Staff CVnCoV CT-0508 (CARMA-0508) ARGX-113 (efgartigimod) Bayer AG CureVac N.V. Boxer Capital EcoR1 Capital Omega Funds Vida Ventures Surveyor Capital Invus Wellington Management OrbiMed Casdin...
Items per page:
1 - 10 of 1180